Related by context. All words. (Click for frequent words.) 70 elotuzumab 70 CIMZIA TM 69 PROMACTA 69 alvimopan 68 forodesine 68 CIMZIA ™ 68 Phase 2b study 68 phase IIb clinical 68 oral ridaforolimus 67 Bezielle 67 HuMax EGFr 67 cannabinor 67 bicifadine 66 HGS ETR1 66 Chemophase 66 LymphoStat B 66 Ophena TM 66 eltrombopag 66 Androxal TM 66 Traficet EN 66 oral prodrug 66 teriflunomide 66 MYDICAR 66 Phase 2a trial 66 ACTEMRA TM 66 denufosol 66 MYDICAR ® 66 TOCOSOL Paclitaxel 66 PEG PAL 66 CoFactor 66 active comparator 66 Phenoptin 65 Elagolix 65 nab paclitaxel 65 CR# vcMMAE 65 BCX# 65 dextofisopam 65 secondary efficacy endpoints 65 ZOLINZA 65 Ophena 65 PREZISTA r 65 custirsen 65 CIMZIA TM certolizumab pegol 65 tezampanel 65 GALNS 65 phase IIa clinical 65 Bicifadine 65 MoxDuo TM IR 65 EOquin 65 valopicitabine 65 viral kinetic 65 Archexin 65 ATACAND 65 #mg QD [001] 65 mapatumumab 65 NGX# 65 cetuximab Erbitux 65 APTIVUS r 65 Phase 2a 65 Pivotal Phase III 65 SVR# 65 teduglutide 65 nalbuphine ER 65 PROCHIEVE 8 65 ISIS # 65 Golimumab 65 Amrubicin 65 Aflibercept 65 phase IIb 64 ularitide 64 phase IIb trial 64 arzoxifene 64 ONTAK 64 ORENCIA ® 64 Capesaris 64 Phase IIa trial 64 RSD# oral 64 ProSavin 64 diabetic neuropathic pain 64 glufosfamide 64 OncoVEX GM CSF 64 HspE7 64 ARB telmisartan 64 adalimumab 64 PREOS 64 Azedra 64 phase IIb study 64 PRT# 64 ibandronate 64 daclizumab 64 Ereska 64 HCV RESPOND 2 64 dirucotide 64 micafungin 64 ACAPODENE 64 desvenlafaxine succinate 64 lumiliximab 64 Ozarelix 64 iniparib 64 Mipomersen 64 PRX # 64 Nasulin 64 Viramidine 64 AZILECT R 64 TDF FTC 64 Ixempra 64 darapladib 64 efficacy endpoint 64 Proellex TM 64 sitaxsentan 64 Azixa 64 Phase 2b clinical 64 FASLODEX 64 LY# [003] 64 FOLFOX4 64 KRN# 64 velafermin 64 #mg BID [001] 64 HER2 positive metastatic breast 64 Zoraxel 64 CCX# 64 Targretin 64 GAMMAGARD 64 oral FTY# 64 FOLFIRI 64 efficacy endpoints 64 dosing cohort 64 PREOS R 64 ARCALYST ® 64 timepoint 64 cetrorelix 64 TELCYTA 63 morphometric vertebral fractures 63 BENICAR HCT 63 atacicept 63 EOquin TM 63 Cimzia TM 63 Q#IR 63 placebo controlled clinical 63 Phase Ib study 63 pharmacokinetic PK study 63 pseudobulbar affect PBA 63 RAPAFLO 63 evaluating tivozanib 63 ACTEMRA 63 Phase 2a clinical 63 GOUT 63 AEGR 63 vandetanib 63 oral rivaroxaban 63 GnRH antagonist 63 Toremifene 63 celgosivir 63 lomitapide 63 R#/MEM # 63 LEP ETU 63 Panzem R NCD 63 metaglidasen 63 Phase 1b trial 63 Pimavanserin 63 BROVANA 63 Fibrillex TM 63 ozarelix 63 apremilast 63 INCB# [001] 63 febuxostat 63 AeroLEF TM 63 COPEGUS 63 talactoferrin 63 GLPG# 63 PEG Interferon lambda 63 Phase IIB 63 confirmatory Phase III 63 bevirimat 63 GetGoal Phase III 63 abatacept 63 microplasmin 63 SILENOR 63 ARCOXIA 63 vicriviroc 63 clevidipine 63 FROVA 63 Adlea 63 tezampanel NGX# 63 TBC# 63 chlorambucil 63 lesinurad 63 canakinumab 63 ALVESCO 63 ABC/3TC 63 ISENTRESS 63 XGEVA 63 AZX# 63 Adalimumab 63 Genz # 63 baminercept 63 ruxolitinib 63 YERVOY 63 trospium 63 TYKERB 63 SUCCEED trial 63 VA# [002] 63 achieved statistical significance 63 GSK# [002] 63 pharmacokinetic PK 63 bosutinib 63 ALGRX 63 huC# DM4 63 Stedivaze 63 BRIM3 63 Tarsa oral calcitonin 63 pertuzumab 63 rindopepimut 63 Neurodex 62 UPLYSO 62 urocortin 2 62 CYCLOSET 62 incyclinide 62 cangrelor 62 HuMax CD# 62 APTIVUS 62 dacetuzumab 62 posaconazole 62 PEG SN# 62 picoplatin 62 Phase IIb trials 62 Phase 1b 62 analgesic efficacy 62 LEVADEX 62 PXD# 62 metastatic CRC 62 Troxatyl 62 dimebon 62 Dextofisopam 62 SCH # 62 sorafenib Nexavar 62 tanespimycin 62 Torisel 62 ribavirin RBV 62 azilsartan medoxomil 62 Rebif ® 62 refractory AML 62 Sanctura XR 62 enoximone 62 BEMA TM Fentanyl 62 #mg dose [002] 62 dose cohort 62 FOLFOX6 62 angiographic outcomes 62 Peginterferon 62 oxymorphone ER 62 Phase IIb clinical 62 LibiGel ® 62 AMEVIVE 62 Pegasys plus Copegus 62 POSIDUR TM 62 MoxDuo IR 62 CANCIDAS 62 administered subcutaneously 62 Empatic 62 Meets Primary Endpoint 62 Phase III Clinical Trial 62 SinuNase 62 TELINTRA 62 virologic response 62 tapentadol ER 62 BRIM2 62 Irinotecan 62 Firazyr 62 lintuzumab 62 octreotide 62 Zerenex 62 oxycodone CR 62 Omigard 62 pradefovir 62 opioid induced bowel dysfunction 62 prucalopride 62 Dyloject TM 62 Plicera 62 docetaxel Taxotere R 62 EVIZON 62 SUPPRELIN R LA 62 GSK# [001] 62 Phase Ib 62 Phase 2b 62 Emselex 62 docetaxel Taxotere ® 62 Triolex 62 Sandostatin LAR 62 ELACYT 62 AzaSite Plus 62 Gabapentin GR 62 caspofungin 62 MERLIN TIMI 62 XIENCE V PROMUS Stent 62 Phase IIa trials 62 Huntexil 62 INCB# [002] 62 Taxotere R 62 vidofludimus 62 Pegasys ® 62 amrubicin 62 Rezular 62 goserelin 62 deforolimus 62 alvespimycin 62 Phase 2b Clinical Trial 62 EFAPROXYN 62 Phase IIIb 62 CRx 62 Bosentan 62 metastatic sarcomas 62 Dasatinib 62 Pemetrexed 62 AVONEX ® 62 Allovectin 7 R 62 NP2 Enkephalin 62 phase IIIb 62 axitinib 62 PRADAXA 62 DAPT 62 Tarceva TM 62 QNEXA 62 INC# 62 Entereg R 62 interferon ribavirin 62 regorafenib 62 catheter occlusion 62 dacarbazine 62 Contrave# 62 methylnaltrexone 62 Orazol 62 Pivotal Phase 62 MGCD# [001] 62 AZD# 62 viral kinetics 62 Proxinium TM 62 Trofex 62 interferon gamma 1b 62 FOSRENOL R 62 novel histone deacetylase 62 SPRYCEL ® 62 CORT # 62 refractory gout 62 mcg kg 62 R# #mg BID 62 CA4P 62 Oral NKTR 62 pomalidomide 62 Anturol TM 62 Urocortin 2 62 Phase 1a clinical 62 OMS#HP 62 abiraterone acetate 62 Phase IIb trial 62 FOLOTYN 62 EDEMA3 62 zonisamide SR 62 ARIMIDEX 62 Nuvion 62 Phase Ib clinical 62 Phase #b/#a trial 62 Dacogen injection 62 HuMax CD4 62 Aptivus ® 62 non metastatic osteosarcoma 62 Zenvia Phase III 61 dose cohorts 61 Xinlay 61 carboplatin paclitaxel 61 JAK inhibitor 61 mGluR5 NAM 61 XmAb# 61 sustained virologic response 61 recurrent herpes labialis 61 DOXIL 61 pexelizumab 61 NLX P# 61 Taxotere ® 61 Phase IIb Trial 61 IIa trial 61 ruboxistaurin 61 Menerba 61 PRISTIQ 61 Xibrom TM 61 peg interferon 61 CLARITY study 61 SILENOR TM 61 Zelrix 61 ALKS 61 budesonide foam 61 Amplimexon 61 Targretin capsules 61 pharmacodynamic properties 61 AVASTIN 61 tecarfarin 61 Vilazodone 61 Azedra TM 61 pemetrexed 61 Aurexis 61 Zenvia ™ 61 cobiprostone 61 docetaxel chemotherapy 61 Androxal 61 tipranavir 61 aclidinium 61 DDP# 61 vernakalant oral 61 omacetaxine mepesuccinate 61 HGS ETR2 61 DAVANAT 61 Phase IIa clinical trials 61 IMGN# 61 atrasentan 61 RoACTEMRA 61 TORISEL 61 Tolerability 61 Certolizumab 61 Catena ® 61 dosing cohorts 61 Phase 2b trial 61 primary efficacy endpoints 61 adalimumab Humira 61 AZASITE 61 paliperidone ER 61 plus dexamethasone 61 IRX 2 61 PEGylated interferon beta 1a 61 enzastaurin 61 NEBIDO 61 Exelixis compounds 61 NATRECOR R 61 rivaroxaban 61 colesevelam HCl 61 SANCTURA XR 61 certolizumab 61 rosuvastatin #mg 61 Nanobody 61 oral deforolimus 61 Ostarine 61 rolofylline 61 oral methylnaltrexone 61 RAPTIVA 61 AEG# 61 Corlux 61 Zyclara 61 Istalol 61 RezularTM 61 Cethromycin 61 degarelix 61 decitabine 61 Phase III trials 61 TYGACIL 61 fallopian tube cancers 61 Chrysalin 61 tocilizumab 61 biologic therapy 61 Androxal ® 61 orBec 61 XL# [003] 61 COLAZAL 61 evaluable subjects 61 selective androgen receptor modulator 61 EGFR TKI 61 Darusentan 61 ONGLYZA ™ 61 INT# [002] 61 brivaracetam 61 plasma kallikrein inhibitor 61 confirmatory Phase 3 61 Hyphanox 61 Anturol 61 pain palliation 61 Dapagliflozin 61 alemtuzumab Campath 61 APPRAISE 61 albinterferon alfa 2b 61 KNS # 61 tolerability profile 61 Elocalcitol 61 MAP# 61 INTELENCE 61 adenosine injection 61 Phase IIa clinical 61 phase IIa 61 Tamibarotene 61 FOLPI 61 AGILECT R 61 ostarine 61 STRIDE PD 61 QD dosing 61 tesofensine 61 YONDELIS 61 PROCHIEVE 61 odanacatib 61 teriparatide 61 IL# PE#QQR 61 pegylated interferons 61 fostamatinib 61 PREGNANT Study 61 non menstrual pelvic 61 metastatic hormone refractory 61 pegloticase 61 ocrelizumab 61 ASA# 61 Phase IIIb clinical 61 Asentar 61 BoNTA 61 Cetrorelix 61 Phase #/#a 61 rALLy 61 Locteron 61 JANUVIA 61 rhThrombin 61 rNAPc2 61 riociguat 61 fenofibric acid 61 alagebrium 61 Relovair 61 Maximum Tolerated Dose 61 QVA# 61 Laquinimod 61 Proellex 61 Multaq R 61 4mg/kg 61 GATTEX 61 AVANDIA 61 CINQUIL 61 LIALDA 60 Frova ® 60 mg QD 60 highly emetogenic 60 entecavir 60 NUEDEXTA 60 Cannabinor 60 CERVARIX 60 QLT# 60 placebo controlled Phase 60 Tekamlo 60 8mg/kg 60 LibiGel 60 FTY# 60 relapsed refractory multiple myeloma 60 lixisenatide 60 ALISTA 60 Seliciclib 60 platelet inhibitor 60 Tyrima 60 MAA submission 60 Amigal 60 statistically significant superiority 60 Multiple Ascending Dose 60 Phase III Trial 60 phase Ib 60 Marqibo 60 Glufosfamide 60 PS# [001] 60 comparator arm 60 pegylated interferon alfa 2a 60 CB2 selective receptor agonist 60 ELND# 60 Ocrelizumab 60 ORENCIA R 60 Frova R 60 ZYBRESTAT 60 Vernakalant 60 salmeterol fluticasone 60 HZT 60 multicenter randomized placebo controlled 60 pitavastatin 60 cilengitide 60 Raptiva ® 60 DexaSite 60 BrachySil 60 INCB# [003] 60 plus methotrexate 60 rFVIIa 60 virus HCV protease inhibitor 60 telaprevir dosing 60 Zemplar Capsules 60 rapid virologic response 60 virologic failure 60 PEGINTRON TM 60 TKM ApoB 60 Pennsaid R 60 zolmitriptan 60 Clolar ® 60 ambrisentan 60 aflibercept 60 QuadraSphere 60 temsirolimus 60 M6G 60 HGS# 60 insulin detemir 60 dextromethorphan quinidine 60 Allovectin 7 60 NVA# 60 DU #b 60 AZILECT ® 60 Vicriviroc 60 Phase 2b clinical trials 60 SAPHRIS 60 clodronate 60 ULORIC 60 Gemzar ® 60 MAXY alpha 60 ICA # 60 APEX PD 60 evaluating mipomersen 60 Efficacy Results 60 randomized Phase IIb 60 certolizumab pegol 60 docetaxel 60 AQ4N 60 plus prednisone 60 cediranib 60 EpiCept NP 1 60 pimecrolimus 60 PASI scores 60 EDEMA3 trial 60 investigational antiplatelet agent 60 Arikace 60 Phase III HEAT 60 octreotide implant 60 SABCS 60 Tanespimycin 60 ixabepilone 60 BEMA Buprenorphine 60 CRLX# 60 imatinib therapy 60 AVINZA 60 VIRAMUNE 60 ritonavir boosted 60 GLP toxicology studies 60 VAPRISOL 60 briakinumab 60 favorable pharmacokinetic profile 60 TMC# [001] 60 ABSORB trial 60 Viprinex TM 60 ISTODAX 60 vilazodone 60 Gliadel Wafer 60 Alocrest 60 peginterferon alfa 2a 60 zalutumumab 60 Xcytrin R 60 FOLFOX6 chemotherapy regimen 60 PSN# [002] 60 AZOR 60 SPIRIT FIRST 60 HRPC 60 Gralise 60 registrational 60 NATRECOR ® 60 Relivar 60 reslizumab 60 Vascular Wrap 60 Phase 1b clinical 60 AGGRASTAT R 60 gout flares 60 primary endpoints 60 antibody MAb 60 Vandetanib 60 Inhalation Solution 60 mRCC 60 SPRYCEL 60 RG# [001] 60 romidepsin 60 Quinamed 60 RSD# iv 60 plus ribavirin 60 BAY #-# 60 Hsp# Inhibitor 60 Anturol ® 60 VELCADE melphalan 60 DXL# 60 pegylated interferon alfa 60 achieved ACR# 60 MAGE A3 ASCI 60 Excellarate 60 INTEGRILIN 60 NUVIGIL 60 aflibercept VEGF Trap 60 RHUCIN 60 Reverset 60 AVONEX 60 ANCHOR trial 60 LymphoStat B TM 60 relapsed MM 60 mg qd 60 tiotropium 60 Sym# 60 BEXXAR 60 sorafenib tablets 60 CINTREDEKIN BESUDOTOX 60 Fludara 60 tafamidis 60 OMNARIS Nasal Spray 60 Vicinium TM 60 CTAP# Capsules 60 oral Xeloda 60 acyclovir Lauriad R 60 Phase IIb clinical trials 60 maximally tolerated dose 60 AZILECT 60 Betaferon R 60 rHuPH# 60 Octreolin 60 Trastuzumab 60 pegylated interferon alpha 2a 60 neratinib 60 vertebral fracture 60 GLYX 60 sargramostim 60 phase 2a 60 SinuNase TM 60 PDE4 inhibitor 60 refractory chronic lymphocytic 60 Navelbine ® 60 Increlex ® 60 cytotoxic therapy 60 nilotinib 60 Diabetic Macular Edema 60 tolvaptan 60 safinamide 60 IND submission 60 ganetespib 60 tamibarotene 60 ascending dose 60 PhosLo 60 mCRC patients 60 diarrhea predominant irritable 60 pegaptanib 60 PDX pralatrexate 60 urate lowering 60 Peg IFN 60 otelixizumab 60 ancrod 60 pivotal Phase III 60 REVLIMID ® 60 Elitek 60 Technosphere Insulin 60 Phase #/#a trial 60 pan HDAC inhibitor 60 IPL# 60 Free Survival PFS 60 MBP# [001] 60 tenofovir emtricitabine 59 eptifibatide 59 GATTEX TM 59 Telaprevir 59 1mg dose 59 Topical Interferon Alpha 2b 59 Carfilzomib 59 ELADUR 59 PegIFN RBV 59 IMA# 59 rilpivirine 59 DepoDur TM 59 PEG INTRON 59 telbivudine 59 bazedoxifene 59 Exalgo 59 mcg QD 59 registrational trial 59 serum phosphorous 59 Viread Emtriva 59 KRAS mutations occur 59 Randomized Phase 59 AGILECT ® 59 octreotide LAR 59 Aloxi injection 59 IMC A# 59 Eltrombopag 59 alfa 2a 59 lintuzumab SGN 59 mg RDEA# 59 ADAGIO study 59 RDEA# 59 Telintra 59 Vaprisol 59 paliperidone palmitate 59 GRN# 59 Ambrisentan 59 Besivance 59 #mg/m# [001] 59 Capecitabine 59 dose titration 59 Pazopanib 59 LATUDA 59 severe gastroparesis 59 GP IIb IIIa inhibitor 59 thymalfasin 59 CRMD# 59 ARIKACE 59 LymphoStat B belimumab 59 EmbraceAC 59 Cellegesic 59 LibiGel Phase III 59 #.#g/day 59 Phase 1a 59 indiplon capsules 59 Northera 59 citalopram hydrobromide 59 BARACLUDE ® 59 cystinosis patients 59 CYPHER R Sirolimus eluting 59 ZYFLO CR 59 GW# [003] 59 interferon beta 1b 59 GnRH agonist 59 LEXIVA r 59 CIPN 59 LEVADEX TM 59 Tasimelteon 59 cetuximab Erbitux R 59 primary efficacy endpoint 59 primary hypercholesterolemia 59 NEVO ™ 59 hypercalcemia 59 peginterferon 59 Myocet 59 sunitinib 59 RSD# 59 primary endpoint 59 Rivaroxaban 59 Phase IIa 59 leukemia AML 59 ONCONASE 59 Actilon 59 lasofoxifene 59 Serada 59 tipranavir r 59 BEMA Granisetron 59 BOLDER II 59 Acute Ischemic Stroke 59 laquinimod 59 Tesetaxel 59 CCR9 antagonist 59 pharmacodynamic 59 telaprevir dosed 59 peginterferon alfa 59 postoperative ileus POI 59 Exherin TM 59 Ventavis 59 compound INCB# 59 ABILIFY ® 59 #mg dose [003] 59 tasimelteon 59 DASISION 59 palonosetron 59 delafloxacin 59 MNTX 59 danoprevir 59 lubiprostone 59 systemically administered 59 Gelnique 59 PEG IFN 59 ponatinib 59 APF# 59 lapatinib Tykerb 59 candesartan cilexetil 59 mipomersen 59 Entereg 59 Alpharadin 59 secondary endpoint 59 lumbar spine BMD 59 vosaroxin 59 eosinophilic asthma 59 tamoxifen therapy 59 Phase IIb 59 KAPIDEX 59 obatoclax 59 oral diclofenac 59 OZURDEX ® 59 Plenaxis TM 59 Pivotal Clinical Trial 59 IRESSA 59 belimumab 59 desvenlafaxine 59 pharmacodynamic effects 59 tolerability 59 lanthanum carbonate 59 uric acid lowering 59 TYSABRI natalizumab 59 Ketotransdel 59 Zenvia TM 59 MEND CABG II 59 neurologic progression 59 Femara letrozole 59 tesmilifene 59 Cimzia ® certolizumab pegol 59 HCV protease inhibitor 59 CYT# potent vascular disrupting 59 Mesafem 59 rALLy trial 59 Tocosol Paclitaxel 59 glatiramer acetate 59 xanthine oxidase inhibitor 59 FOSRENOL 59 metastatic castration resistant 59 varespladib 59 Excellarate TM 59 albiglutide 59 confirmatory clinical 59 noninferiority 59 omega interferon 59 doripenem 59 Atrasentan 59 rEV# 59 fluoropyrimidine 59 Onalta ™ 59 KRAS status 59 ZACTIMA 59 BLA filing 59 postoperative chemotherapy 59 cetuximab Erbitux ® 59 Imprime PGG 59 L BLP# 59 Prosaptide 59 Taxol paclitaxel 59 Ceplene/IL-2 59 visilizumab 59 intravitreal injection 59 gadobutrol 59 assessing T DM1 59 Tezampanel 59 dosage regimens 59 GLP1 agonist 59 RELOVAIR ™ 59 keloid scarring 59 histone deacetylase HDAC inhibitor 59 infusional 5-FU/LV 59 mg BID 59 Dual Opioid 59 azacitidine 59 CAELYX 59 ONGLYZA 59 TYZEKA 59 peginterferon alfa 2b 59 ALTACE 59 Betaferon ® 59 clinical pharmacology studies 59 Tekturna HCT 59 metastatic HRPC 59 AP# [003] 59 dose escalation 59 panitumumab Vectibix 59 TriRima 59 Xanafide 59 PRIMO CABG 59 pegylated interferon alpha 59 Icatibant 59 NKTR 59 pharmacokinetic profile 59 RECOTHROM 59 dose limiting toxicities 59 SEROQUEL 59 HepeX B 59 Dabigatran etexilate 59 generation purine nucleoside 59 pramlintide metreleptin combination 59 dose escalation Phase 59 GRALISE 59 pharmacokinetic PK profile 59 ENDEAVOR II 59 gefitinib Iressa 59 Zoledronic acid 59 PegIntron 59 Pegylated Interferon 59 Abbott HUMIRA 59 Monotherapy 59 PRX# 59 BYDUREON 59 SYMBICORT 59 Trofex TM 59 SERCA2a 59 rilonacept 59 BCIRG 59 SYMMETRY trial 59 Achieves Primary Endpoint 59 Sulonex 59 pegylated liposomal doxorubicin 59 LEVADEX ™ 59 SPIRIVA ® 59 mg/m2 dose 59 investigational monoclonal antibody 59 PSMA ADC 59 T Pred 59 edoxaban 59 MGCD# [002] 59 IV bolus 59 orally bioavailable 59 T DM1 59 mg Proellex 59 lenalidomide Revlimid R 59 ALN TTR# 59 anti TNF alpha